Cetermin - Insmed
Alternative Names: Betakine; Recombinant transforming growth factor-beta-2; TGF-beta-2; Transforming growth factor-beta-2Latest Information Update: 31 Mar 2022
At a glance
- Originator Insmed
- Developer Enzon Pharmaceuticals; Insmed; Sanofi
- Class Transforming growth factors
- Mechanism of Action Immunosuppressants; Intercellular signalling peptide and protein stimulants; Osteogenesis stimulants; Transforming growth factor beta2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Age-related macular degeneration; Autoimmune disorders; Cancer; Diabetic foot ulcer; Eye disorders; Multiple sclerosis; Pleural effusion; Postmenopausal osteoporosis; Rheumatoid arthritis; Skin disorders; Transplant rejection
Most Recent Events
- 10 Jan 2006 Discontinued - Phase-I for Multiple sclerosis in USA (IV)
- 10 Jan 2006 Discontinued - Phase-II for Diabetic foot ulcer in USA (unspecified route)
- 10 Jan 2006 Discontinued - Preclinical for Pleural effusion in Australia (unspecified route)